Published in Am J Trop Med Hyg on May 01, 2008
Operational strategies to achieve and maintain malaria elimination. Lancet (2010) 6.48
Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev (2009) 3.41
Designing the next generation of medicines for malaria control and eradication. Malar J (2013) 2.25
Application of mobile-technology for disease and treatment monitoring of malaria in the "Better Border Healthcare Programme". Malar J (2010) 1.82
Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes. Proc Natl Acad Sci U S A (2010) 1.74
Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J (2012) 1.61
Primaquine in vivax malaria: an update and review on management issues. Malar J (2011) 1.53
A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of plasmodium vivax in Northwest Frontier Province, Pakistan. PLoS One (2008) 1.43
Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother (2012) 1.30
Plasmodium vivax treatments: what are we looking for? Curr Opin Infect Dis (2011) 1.16
A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg (2010) 1.06
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax. Antimicrob Agents Chemother (2008) 1.03
Efficacy of three different regimens of primaquine for the prevention of relapses of Plasmodium vivax malaria in the Amazon Basin of Peru. Am J Trop Med Hyg (2014) 0.98
Use of a rhesus Plasmodium cynomolgi model to screen for anti-hypnozoite activity of pharmaceutical substances. Am J Trop Med Hyg (2012) 0.97
Clinical characteristics of vivax malaria and analysis of recurred patients. Infect Chemother (2013) 0.96
Efficacy and safety of artemisinin combination therapy (ACT) for non-falciparum malaria: a systematic review. Malar J (2014) 0.95
Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency. BMC Med (2015) 0.94
Management of relapsing Plasmodium vivax malaria. Expert Rev Anti Infect Ther (2016) 0.88
G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria. PLoS Negl Trop Dis (2015) 0.85
Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev (2009) 0.84
Improving the radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg (2014) 0.84
Pharmacokinetic properties of single-dose primaquine in Papua New Guinean children: feasibility of abbreviated high-dose regimens for radical cure of vivax malaria. Antimicrob Agents Chemother (2013) 0.82
Relapse of imported Plasmodium vivax malaria is related to primaquine dose: a retrospective study. Malar J (2012) 0.82
Primaquine treatment and relapse in Plasmodium vivax malaria. Pathog Glob Health (2016) 0.81
Antirelapse Efficacy of Various Primaquine Regimens for Plasmodium vivax. Malar Res Treat (2014) 0.80
Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infect Dis (2015) 0.79
Genetic diversity among Plasmodium vivax isolates along the Thai-Myanmar border of Thailand. Malar J (2016) 0.75
Diagnosis and Treatment of Plasmodium vivax Malaria. Am J Trop Med Hyg (2016) 0.75
Increased bioavailability of primaquine using poly(ethylene oxide) matrix extended-release tablets administered to beagle dogs. Ann Trop Med Parasitol (2011) 0.75
The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg (2001) 11.74
Primaquine therapy for malaria. Clin Infect Dis (2004) 4.66
Disposition of chloroquine in man after single intravenous and oral doses. Br J Clin Pharmacol (1983) 2.59
High rate of Plasmodium vivax relapse following treatment of falciparum malaria in Thailand. Lancet (1987) 2.52
Mitigation of the haemolytic effect of primaquine and enhancement of its action against exoerythrocytic forms of the Chesson strain of Piasmodium vivax by intermittent regimens of drug administration: a preliminary report. Bull World Health Organ (1960) 2.50
Can primaquine therapy for vivax malaria be improved? Trends Parasitol (2003) 2.31
Diagnosis and management of G6PD deficiency. Am Fam Physician (2005) 2.28
The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. Trends Parasitol (2004) 2.16
Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis (1995) 1.87
Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg (1982) 1.85
Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria. Br J Clin Pharmacol (1983) 1.77
In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg (1997) 1.74
Toxicity of primaquine in Caucasians. J Am Med Assoc (1952) 1.74
International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol (1979) 1.71
Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg (2003) 1.54
Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann Trop Med Parasitol (1999) 1.44
High dose of primaquine in primaquine resistant vivax malaria. Trans R Soc Trop Med Hyg (1994) 1.33
Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg (1999) 1.31
Effect of primaquine standard dose (15 mg/day for 14 days) in the treatment of vivax malaria patients in Thailand. Southeast Asian J Trop Med Public Health (2001) 1.27
Can treatment of P. vivax lead to a unexpected appearance of falciparum malaria? Southeast Asian J Trop Med Public Health (2001) 1.25
Hidden Plasmodium falciparum infections. Southeast Asian J Trop Med Public Health (1999) 1.25
Chloroquine treatment of severe malaria in children. Pharmacokinetics, toxicity, and new dosage recommendations. N Engl J Med (1988) 1.22
Primaquine-tolerant vivax malaria in Thailand. Ann Trop Med Parasitol (1997) 1.06
Consensus recommendation on the treatment of malaria in Southeast Asia. Southeast Asian J Trop Med Public Health (1998) 1.03
Atovaquone and proguanil hydrochloride followed by primaquine for treatment of Plasmodium vivax malaria in Thailand. Trans R Soc Trop Med Hyg (2000) 0.98
Treatment of Plasmodium vivax malaria--time for a change? Trans R Soc Trop Med Hyg (1997) 0.88
The course of primaquine-induced haemolysis in G-6-PD-deficient Thais. J Med Assoc Thai (1973) 0.84
Relapse of vivax malaria treated with primaquine and report of one case of cyanosis (methemoglobinemia) due to primaquine. Am J Med Sci (1954) 0.80
Current challenges in drug-resistant malaria. J Postgrad Med (2006) 0.80
WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet (2004) 9.27
Acquired immunity to malaria. Clin Microbiol Rev (2009) 6.24
The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis (2010) 6.23
Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis (2009) 5.90
A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis (2012) 5.24
Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis (2007) 4.35
Deployment of early diagnosis and mefloquine-artesunate treatment of falciparum malaria in Thailand: the Tak Malaria Initiative. PLoS Med (2006) 3.83
Sensitive and inexpensive molecular test for falciparum malaria: detecting Plasmodium falciparum DNA directly from heat-treated blood by loop-mediated isothermal amplification. Clin Chem (2005) 3.75
A randomized, controlled study of a simple, once-daily regimen of dihydroartemisinin-piperaquine for the treatment of uncomplicated, multidrug-resistant falciparum malaria. Clin Infect Dis (2005) 3.15
Demographic risk factors for severe and fatal vivax and falciparum malaria among hospital admissions in northeastern Indonesian Papua. Am J Trop Med Hyg (2007) 3.07
Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood (2010) 3.03
Iron supplementation during pregnancy, anemia, and birth weight: a randomized controlled trial. Am J Clin Nutr (2003) 2.95
G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med (2012) 2.93
Primaquine: report from CDC expert meeting on malaria chemoprophylaxis I. Am J Trop Med Hyg (2006) 2.86
Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J Infect Dis (2004) 2.82
Central role of the spleen in malaria parasite clearance. J Infect Dis (2002) 2.80
In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother (2004) 2.77
Mefloquine is highly efficacious against chloroquine-resistant Plasmodium vivax malaria and Plasmodium falciparum malaria in Papua, Indonesia. Clin Infect Dis (2006) 2.76
Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol (2010) 2.75
Use of peroxisome proliferator-activated receptor gamma agonists as adjunctive treatment for Plasmodium falciparum malaria: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2009) 2.66
Very high risk of therapeutic failure with chloroquine for uncomplicated Plasmodium falciparum and P. vivax malaria in Indonesian Papua. Am J Trop Med Hyg (2003) 2.49
Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet (2010) 2.48
An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. Am J Trop Med Hyg (2003) 2.47
Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J Immunol (2004) 2.33
The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. Am J Trop Med Hyg (2004) 2.32
Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Antimicrob Agents Chemother (2003) 2.26
Bimodal cardiac dysfunction in an animal model of iron overload. J Lab Clin Med (2002) 2.23
Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria. Blood (2002) 2.19
Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. Antimicrob Agents Chemother (2004) 2.17
Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malar J (2005) 2.15
Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am J Trop Med Hyg (2003) 2.10
A systematic overview of published antimalarial drug trials. Trans R Soc Trop Med Hyg (2004) 2.02
Serum angiopoietin-1 and -2 levels discriminate cerebral malaria from uncomplicated malaria and predict clinical outcome in African children. PLoS One (2009) 1.93
Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood (2011) 1.92
Malaria diagnosis: a brief review. Korean J Parasitol (2009) 1.86
G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol (2013) 1.85
Geographical variation in Plasmodium vivax relapse. Malar J (2014) 1.73
Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J Infect Dis (2004) 1.71
Keys to success for a school-based malaria control program in primary schools in Thailand. Parasitol Int (2006) 1.71
Randomized comparison of artesunate and quinine in the treatment of severe falciparum malaria. Clin Infect Dis (2003) 1.61
Extended linkage disequilibrium surrounding the hemoglobin E variant due to malarial selection. Am J Hum Genet (2004) 1.61
Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J (2012) 1.61
Malaria distribution, prevalence, drug resistance and control in Indonesia. Adv Parasitol (2011) 1.61
Whole blood angiopoietin-1 and -2 levels discriminate cerebral and severe (non-cerebral) malaria from uncomplicated malaria. Malar J (2009) 1.59
Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Trop (2004) 1.58
Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains. Exp Parasitol (2005) 1.58
World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J (2007) 1.56
Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. Am J Trop Med Hyg (2003) 1.54
Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother (2008) 1.50
Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes. Proc Natl Acad Sci U S A (2002) 1.50
Natural human humoral response to salivary gland proteins of Anopheles mosquitoes in Thailand. Acta Trop (2006) 1.47
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. Antimicrob Agents Chemother (2006) 1.46
Transmission-blocking activities of quinine, primaquine, and artesunate. Antimicrob Agents Chemother (2006) 1.43
In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. Am J Trop Med Hyg (2004) 1.43
An Ethiopian pattern of human adaptation to high-altitude hypoxia. Proc Natl Acad Sci U S A (2002) 1.43
Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients. PLoS Med (2006) 1.42
Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J (2013) 1.37
Deferoxamine promotes survival and prevents electrocardiographic abnormalities in the gerbil model of iron-overload cardiomyopathy. J Lab Clin Med (2003) 1.35
Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse. Clin Infect Dis (2004) 1.34
Limited polymorphism in the dihydropteroate synthetase gene (dhps) of Plasmodium vivax isolates from Thailand. Antimicrob Agents Chemother (2005) 1.33
Evaluation of a real-time polymerase chain reaction assay for the diagnosis of malaria in patients from Thailand. Am J Trop Med Hyg (2005) 1.33
Mekong malaria. II. Update of malaria, multi-drug resistance and economic development in the Mekong region of Southeast Asia. Southeast Asian J Trop Med Public Health (2003) 1.31
Plasmodium falciparum malaria endemicity in Indonesia in 2010. PLoS One (2011) 1.31
Helminth infections are associated with protection from cerebral malaria and increased nitrogen derivatives concentrations in Thailand. Am J Trop Med Hyg (2002) 1.31
A biologic basis for integrated malaria control. Am J Trop Med Hyg (2002) 1.30
Fcgamma receptor IIA and IIIB polymorphisms are associated with susceptibility to cerebral malaria. Parasitol Int (2002) 1.30
Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother (2012) 1.30
A randomized, double-blind, placebo-controlled, dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin Infect Dis (2003) 1.28
A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis (2005) 1.27
Histopathology of fatal respiratory distress caused by Plasmodium vivax malaria. Am J Trop Med Hyg (2009) 1.27
Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis (2010) 1.27
Real-world therapies and the problem of vivax malaria. N Engl J Med (2008) 1.26
Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis (2002) 1.25
Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen population in Thailand. Malar J (2008) 1.25
Novel Plasmodium vivax dhfr alleles from the Indonesian Archipelago and Papua New Guinea: association with pyrimethamine resistance determined by a Saccharomyces cerevisiae expression system. Antimicrob Agents Chemother (2005) 1.24
Efficacy of DB289 in Thai patients with Plasmodium vivax or acute, uncomplicated Plasmodium falciparum infections. J Infect Dis (2005) 1.22
Plasmodium vivax adherence to placental glycosaminoglycans. PLoS One (2012) 1.22
Are extensive T cell epitope polymorphisms in the Plasmodium falciparum circumsporozoite antigen, a leading sporozoite vaccine candidate, selected by immune pressure? J Immunol (2005) 1.22
CD36 polymorphism is associated with protection from cerebral malaria. Am J Hum Genet (2002) 1.21
Reduced levels of transforming growth factor-beta1, interleukin-12 and increased migration inhibitory factor are associated with severe malaria. Acta Trop (2004) 1.20
Short report: detection of Orientia tsutsugamushi in clinical samples by quantitative real-time polymerase chain reaction. Am J Trop Med Hyg (2005) 1.19
Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet (2002) 1.18
New haplotypes of the Plasmodium falciparum chloroquine resistance transporter (pfcrt) gene among chloroquine-resistant parasite isolates. Am J Trop Med Hyg (2003) 1.18
Azithromycin combination therapy with artesunate or quinine for the treatment of uncomplicated Plasmodium falciparum malaria in adults: a randomized, phase 2 clinical trial in Thailand. Clin Infect Dis (2006) 1.17
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17